Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Although Moderna Inc. doesn’t yet have any marketed products, analysts are encouraged that the Cambridge, MA, firm that was first into the clinic with a vaccine for the novel coronavirus SARS-CoV-2 can succeed in developing a COVID-19 vaccine based on findings from its development of vaccines for other infectious diseases.
The company will be providing more details on its vaccines program overall, including the mRNA-1273 coronavirus vaccine, at a 14...
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.
Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.
